GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma
September 14 2016 - 9:15AM
Business Wire
Trial to test candidate for second blood
cancer type among patients responding poorly to standard
therapy
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced it has dosed
its first patient in a Phase 1 clinical trial of its novel
E-selectin antagonist, GMI-1271, combined with bortezomib-based
chemotherapy, for multiple myeloma. The trial marks a second
application for GMI-1271, which already is undergoing clinical
study as a potential treatment for acute myeloid leukemia
(AML).
The newly initiated multi-center, open-label dose escalation
trial, which has begun in Ireland, will measure the efficacy,
safety and pharmacokinetics of GMI-1271 in combination with
chemotherapy among patients who have been diagnosed with multiple
myeloma and have not responded well to standard chemotherapy. The
company anticipates enrolling 24 participants in the trial.
“This new clinical trial provides an opportunity to evaluate
GMI-1271’s ability to treat hematological cancers beyond AML,”
said Dr. John Quinn, Consultant Haematologist, Beaumont
Hospital, Dublin, Ireland. “Preclinical studies showed promise
for E-selectin antagonists against other types of cancers, so this
pilot study in multiple myeloma may determine if GMI-1271 may
become part of a bortezomib rescue treatment for patients not
responding to standard regimens.” Beaumont Hospital is one of
a number of Blood Cancer Network Ireland (BCNI)
sites participating in this study.
In preclinical studies, mice with multiple myeloma that were
treated with GMI-1271 and bortezomib showed improvement in survival
compared to those treated with bortezomib alone. Furthermore, in
mice with myeloma resistant to treatment with bortezomib, addition
of GMI-1271 restored bortezomib sensitivity. In addition, blood
samples from individuals with multiple myeloma showed increases in
cell surface expression of E-selectin carbohydrate ligands when
cancer had relapsed, indicating E-selectin as a promising target
for reducing drug resistance in certain groups of patients who have
the disease.
Multiple myeloma is a neoplastic proliferation of plasma cells
derived from bone marrow. The cells ultimately infiltrate a number
of organs and lead to bone marrow destruction and failure. It is
the most common tumor in the bone and the second most-common blood
cancer in the US and Europe. According to EU data from 2012, 39,000
new diagnoses were made for multiple myeloma, and 24,000 people
died from the disease there. Most patients currently ultimately
relapse from chemotherapy, and the disease is not considered
curable using current approaches.
In the Phase 1 study, participants will include individuals who
have been diagnosed with multiple myeloma and undergone
bortezomib-based therapy with inadequate responses. The patients
will receive one of four doses of GMI-1271 in combination with
bortezomib, intravenously concurrently with bortezomib treatment.
They will be followed after treatment to measure safety endpoints
and efficacy.
About GMI-1271
GMI-1271 is designed to block E-selectin (an adhesion molecule
on cells in the bone marrow) from binding with blood cancer cells
as a targeted approach to disrupting well-established mechanisms of
leukemic cell resistance within the bone marrow microenvironment.
Preclinical research points to the drug’s potential role in moving
cancerous cells out of the protective environment of the bone
marrow where they hide and escape the effects of chemotherapy. In
preclinical studies using animal models of AML, the results of
which were presented at meetings of the American Society of
Hematology (ASH), GMI-1271 was also associated with a
reduction of chemotherapy-induced neutropenia and
chemotherapy-induced mucositis.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on sickle cell disease and cancer. GlycoMimetics’ most advanced
drug candidate, rivipansel, a pan-selectin antagonist, is being
developed for the treatment of vaso-occlusive crisis in sickle cell
disease and is being evaluated in a Phase 3 clinical trial being
conducted by its strategic collaborator, Pfizer. GlycoMimetics’
wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated in an ongoing Phase 1/2 clinical trial as a
potential treatment for AML. GlycoMimetics has also recently
initiated a clinical trial with a third drug candidate, GMI-1359, a
combined CXCR4 and E-selectin antagonist. GlycoMimetics is located
in Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1271. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
availability and timing of data from ongoing clinical trials, the
uncertainties inherent in the initiation of future clinical trials,
whether interim results from a clinical trial will be predictive of
the final results of the trial or results of early clinical trials
will be indicative of the results of future trials, expectations
for regulatory approvals, availability of funding sufficient for
GlycoMimetics' foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect
the availability or commercial potential of GlycoMimetics' drug
candidates and other factors discussed in the "Risk Factors"
section of GlycoMimetics' Annual Report on Form 10-K that was filed
with the U.S. Securities and Exchange
Commission on February 29, 2016, and other
filings GlycoMimetics makes with the Securities and
Exchange Commission from time to time. In addition, the
forward-looking statements included in this press release represent
GlycoMimetics' views as of the date
hereof. GlycoMimetics anticipates that subsequent events
and developments may cause its views to change. However,
while GlycoMimetics may elect to update these
forward-looking statements at some point in the future,
GlycoMimetics specifically disclaims any obligation to do so,
except as may be required by law. These forward-looking statements
should not be relied upon as representing GlycoMimetics' views as
of any date subsequent to the date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160914005668/en/
GlycoMimetics, Inc.Investor Contact:Shari
AnnesPhone: 650-888-0902Email: sannes@annesassociates.comorMedia
Contact:Jamie Lacey-MoreiraPhone: 410-299-3310Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024